Related Experiment Video
Updated: Jun 14, 2025
08:56
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
52.2K
BRD4: an effective target for organ fibrosis
Qun Wei1, Cailing Gan1, Meng Sun1
1Laboratory of Gastrointestinal Cancer and Liver Disease, Department of Gastroenterology and Hepatology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Biomarker Research
|August 30, 2024
Summary
Targeting bromodomain-containing protein 4 (BRD4), a key epigenetic regulator, shows promise for treating organ fibrosis. BRD4 inhibition presents a potential antifibrotic strategy, though clinical application faces challenges.
Area of Science:
- Epigenetics
- Molecular Biology
- Drug Discovery
Background:
- Fibrosis, a major cause of organ failure and mortality, lacks effective treatments beyond pulmonary indications.
- Epigenetic alterations, particularly involving bromodomain and extra-terminal domain (BET) proteins, are critical in fibrosis development.
- Bromodomain-containing protein 4 (BRD4) is a key BET protein involved in pro-fibrotic gene expression.
Purpose of the Study:
- To review the role of BET proteins and BRD4 in organ fibrosis.
- To discuss the progress of BRD4 inhibitors in preclinical and clinical fibrosis research.
- To evaluate the therapeutic potential and challenges of targeting BRD4 for antifibrotic strategies.
Main Methods:
- Literature review of studies on BET proteins, BRD4, and fibrosis.
- Analysis of preclinical data on BRD4 inhibition in fibrotic models.
- Examination of current BRD4 inhibitors and their clinical development status.
Main Results:
- BRD4 regulates genes associated with inflammation and fibrosis.
- Inhibition of BRD4 has demonstrated significant antifibrotic effects in preclinical studies.
- Several BRD4 inhibitors are under investigation, but none are yet approved for clinical use in fibrosis.
Conclusions:
- Targeting BRD4 is a feasible and promising antifibrotic strategy.
- Further research and clinical trials are needed to overcome challenges and realize the therapeutic potential of BRD4 inhibitors for fibrotic diseases.
